Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

ARA-290 Clinical Trials 2026: [Peptide Therapeutic] Comparison

Understanding where ARA-290 sits relative to other investigational peptides clarifies why its clinical trajectory diverged from compounds with similar mechanistic appeal. The table below compares ARA-290 to peptides targeting adjacent therapeutic spaces in neu

This comparison does not assign a generated winner or score.

  • Understanding where ARA-290 sits relative to other investigational peptides clarifies why its clinical trajectory diverged from compounds with similar mechanistic appeal. The table below compares ARA-290 to peptides targeting adjacent therapeutic spaces in neuropathy, tissue repair, and metabolic dysfunction.
  • ARA-290
  • Innate repair receptor agonist (EPOR/CD131 heterodimer activation)
  • Investigator-initiated only; commercial development discontinued 2019
  • 2–4mg SC three times weekly
  • Positive nerve fiber density biomarkers; failed pain reduction endpoints in Phase II sarcoidosis trial (RESOLVE, 2019)
  • Mechanism validated but clinically orphaned. Biomarker improvements didn't translate to patient-meaningful endpoints within FDA frameworks
  • BPC-157
  • Gastric peptide derivative; angiogenesis and tissue healing modulation
  • Preclinical and early human case series only; no registered Phase II trials
  • 250–500mcg SC or oral daily in case reports
  • Promising animal models for tendon healing and GI protection; human data limited to case reports and uncontrolled observations
  • Strong preclinical foundation but lacks the controlled clinical trial infrastructure ARA-290 had. Remains entirely in the investigational research space
  • Thymosin Alpha-1
  • Thymic peptide; immune modulation via T-cell maturation
  • Approved in 30+ countries (not FDA-approved); ongoing Phase III sepsis trials
  • 1.6mg SC twice weekly
  • Demonstrated efficacy in hepatitis B/C and as vaccine adjuvant in international trials; variable FDA trial results
  • Has achieved regulatory approval outside the U.S. where endpoint flexibility allowed. Shows the jurisdictional variability ARA-290 couldn't navigate
  • Cerebrolysin
  • Neurotrophic peptide mixture from porcine brain; BDNF/NGF-like activity
  • Approved in 40+ countries; used clinically for stroke and dementia
  • 10–30mL IV daily for 10–20 days
  • Meta-analyses show modest cognitive improvements in post-stroke and dementia cohorts; heterogeneity limits interpretation
  • Complexity of peptide mixture makes mechanism attribution difficult. But real-world use outside the U.S. demonstrates clinical utility despite mechanistic ambiguity
  • Epoetin Alfa (rHuEPO)
  • Full-length erythropoietin; both hematopoietic and tissue-protective effects
  • FDA-approved for anemia; investigational for neuroprotection
  • 40,000–150,000 units SC weekly (anemia dosing)
  • Approved anemia indication well-established; neuroprotection trials showed safety concerns (thrombosis, hypertension) at tissue-protective doses
  • ARA-290 was designed specifically to separate EPO's tissue protection from its hematologic risks. But losing the erythropoietic effect also eliminated a measurable surrogate endpoint
  • The table reveals ARA-290's paradox: it was engineered to be safer than EPO but lost the built-in biomarker (hemoglobin/hematocrit) that makes EPO's effects immediately quantifiable. Nerve fiber density and corneal confocal microscopy are elegant research tools but lack the clinical immediacy of a rising hemoglobin level or a standardized pain scale reduction that regulators recognize as approval-worthy.